crinetics.png
Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
September 27, 2021 07:30 ET | Crinetics Pharmaceuticals, Inc.
- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company...
XOMA-Logo-Final.png
New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting
November 08, 2016 09:00 ET | XOMA Ltd.
Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone...
Rockwell Medical, Inc. logo
Rockwell Medical Enters Into Exclusive License Agreement With Wanbang Biopharmaceutical Co., Ltd. to Commercialize Triferic® in China
February 16, 2016 08:00 ET | Rockwell Medical, Inc.
WIXOM, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...